Indication: Elopag, also recognized as Eltrombopag according to the International Nonproprietary Name (INN), is indicated to manage thrombocytopenia in adults with chronic immune thrombocytopenia (ITP) who haven’t responded adequately to corticosteroids, immunoglobulins, or splenectomy.

Pharmacology: Operating as a thrombopoietin receptor agonist, Elopag boosts platelet production by interacting with the thrombopoietin receptor’s transmembrane domain. This engagement triggers intracellular signaling pathways, fostering megakaryocyte growth and differentiation, ultimately enhancing platelet production.

Dosage and Administration: The recommended dosage of Elopag for adults with chronic ITP is 50 mg orally once daily, adjusted based on individual response to attain and sustain the target platelet count. It can be taken with or without food, preferably at the same time daily.

Interactions: Elopag may interact with medications affecting cytochrome P450 enzymes, notably CYP2C8 and CYP3A4. Concurrent use with potent CYP2C8 inhibitors or inducers should be avoided, and caution exercised with drugs heightening bleeding risk.

Side Effects: Common side effects include headache, fatigue, nausea, diarrhea, upper respiratory tract infections, and peripheral edema. Serious adverse reactions like thromboembolic events, hepatotoxicity, and cataracts may occur.

Precautions and Warnings:

• Thromboembolic event signs warrant close monitoring, especially in high-risk patients.
• Regular liver function tests are recommended due to potential hepatotoxicity.
• Ophthalmic monitoring is advised, considering the risk of cataract development.
• Caution is advised in chronic liver disease patients, potentially at higher risk of portal vein thrombosis with Elopag.

Overdose Effect: In case of overdose, supportive care is recommended. Specific antidotes are unavailable, necessitating close monitoring for adverse reactions, with symptomatic treatment as necessary.